Combinatorial approach to treatment of melanoma

Michelle T Ashworth; Adil I Daud

doi:10.1016/j.hoc.2014.03.002

Combinatorial approach to treatment of melanoma

Hematol Oncol Clin North Am. 2014 Jun;28(3):601-12. doi: 10.1016/j.hoc.2014.03.002.

Authors

Michelle T Ashworth¹, Adil I Daud²

Affiliations

¹ Hematology/Oncology, University of California, San Francisco, 505 Parnassus Avenue, M1286 MS1270, San Francisco, CA 94143, USA.
² Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA. Electronic address: [email protected].

PMID: 24880950
DOI: 10.1016/j.hoc.2014.03.002

Abstract

There are multiple effective and well-tolerated systemic therapy treatments for the treatment of advanced melanoma, as well as new immunotherapy and targeted therapy agents in clinical trials. Traditional cytotoxic chemotherapy and targeted BRAF inhibitors can increase antigen presentation and can rebalance the intratumoral immune milieu. The combination of pulsed cytotoxic therapy and immunotherapy is a logical next step in designing treatment regimens. Combination radiotherapy and immunotherapy also has experimental and clinical support. The standard of care for patients with advanced melanoma remains participation in clinical trials in order to enhance understanding of the effectiveness and toxicities of combination regimens.

Keywords: BRAF; Combination therapy; Immunotherapy; Melanoma; Mitogen-activated extracellular kinase; Targeted therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Humans
Immunotherapy / methods
Melanoma / therapy*
Molecular Targeted Therapy / methods
Skin Neoplasms / therapy*
Survival Analysis
Treatment Outcome